Recent life science and diagnostic acquisitions have included Beckman Coulter, Pall, and Cepheid. In early 2020, Danaher completed the acquisition of GE Biopharma, now called Cytiva, which fills ...

Danaher faced a disappointing 2024 ... they have shown five consecutive quarters of improvement in Bioprocessing orders. Cepheid, for its part, continues to experience double-digit growth ...

Danaher Corp (DHR) reports robust cash flow and strategic acquisitions, despite facing revenue headwinds and market ...

Cepheid's Multiplex Panel enables physicians ... talented team and strong balance sheet, all powered by the Danaher Business System, we feel well-positioned to deliver long-term shareholder ...

Investors with a lot of money to spend have taken a bullish stance on Danaher DHR. And retail traders should know. We noticed this today when the positions showed up on publicly available options ...

KKR builds stake in Henry Schein, reaches deal to add board seats Danaher on Wednesday missed Wall Street estimates for fourth-quarter profit due to soft demand for tools and services used in drug ...

For 2025, Danaher's 3% core revenue growth outlook ... growth than we had anticipated, including at Cepheid where it expects a decline in respiratory sales. While we still expect some adjusted ...